STOCK TITAN

SION insider sales: 33,000 shares proposed; recent 10b5-1 trades disclosed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Sionna Therapeutics (SION) Form 144 notice reports a proposed sale of 33,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $793,980 and an approximate sale date of 08/26/2025 on NASDAQ. The shares were acquired on 06/15/2023 upon exercise of stock options and paid in cash. The filer also disclosed recent Rule 10b5-1 sales by the same account: 17,500 shares sold on 08/20/2025 for $397,152 and 34,500 shares sold on 08/19/2025 for $727,112.80. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information and references a possible 10b5-1 plan adoption date field (not populated in the text provided).

Positive

  • None.

Negative

  • Insider sale disclosed: Proposed Rule 144 sale of 33,000 shares (aggregate market value $793,980) scheduled for 08/26/2025.
  • Recent insider selling: Two 10b5-1 sales in August 2025 totaling 52,000 shares for gross proceeds of $1,124,264.80.

Insights

TL;DR: Insiders are executing Rule 144 and 10b5-1 sales totaling 85,000 shares recently; proposed sale is 33,000 shares (approx. $794k).

The filing documents a routine Rule 144 notice for sale of 33,000 common shares acquired via exercised options on 06/15/2023. The broker listed is Morgan Stanley Smith Barney and the transaction is slated for NASDAQ on 08/26/2025. The filing also discloses two recent 10b5-1-plan sales totaling 52,000 shares with combined gross proceeds of $1,124,264.80. For investors, these are insider liquidity events rather than company operational disclosures; they do not, by themselves, provide information about company performance or governance changes.

TL;DR: The filing reflects compliance with Rule 144 and 10b5-1 procedures; no disclosure of material undisclosed information is claimed.

The signer makes the standard representation about lack of undisclosed material adverse information and references a 10b5-1 plan date field (not filled in the provided content). The presence of executed 10b5-1 sales suggests prearranged trading instructions, which typically reduce the likelihood that these trades signal undisclosed insider knowledge. There is no indication in this filing of unusual timing, related-party transactions, or other governance red flags based solely on the presented data.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does SION Form 144 report?

The filing reports a proposed sale of 33,000 common shares through Morgan Stanley Smith Barney with aggregate market value $793,980, approximate sale date 08/26/2025.

How were the 33,000 shares acquired?

The shares were acquired on 06/15/2023 through previously exercised stock options and payment was in cash.

Were there other recent sales by the same person?

Yes. Two 10b5-1 sales: 34,500 shares sold on 08/19/2025 for $727,112.80 and 17,500 shares sold on 08/20/2025 for $397,152.00.

Which broker is handling the proposed sale?

The broker listed is Morgan Stanley Smith Barney LLC, address: Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004.

Does the filing state the seller has undisclosed material information?

The filing includes the standard seller representation that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Sionna Therapeutics

NASDAQ:SION

SION Rankings

SION Latest News

SION Latest SEC Filings

SION Stock Data

1.61B
30.22M
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM